2024年9月1日 · Stroke prevention with direct-acting oral anticoagulant agents in patients with atrial fibrillation confers a risk of bleeding and limits their use. Asundexian, an activated factor …

Asundexian 50 mg once daily was inferior for prevention of stroke and systemic embolism compared with Apixaban in patients with atrial fibrillation at high risk for stroke. The majority of …

Asundexian is a Factor XIa inhibitor developed by Bayer to prevent stroke. [1] Asundexian efficacy and safety in patients have been evaluated in two clinical trial programs: phase IIb PACIFIC …

3 天之前 · Bayer is pressing ahead with a phase 3 trial of its oral Factor XIa inhibitor asundexian, a new anticoagulant, despite missing efficacy targets in two mid-stage studies.

3 天之前 · Bayer has decided to discontinue a phase 3 trial of its oral Factor XIa inhibitor asundexian in patients with atrial fibrillation (AF), after an interim analysis concluded the novel...

2022年5月16日 · Asundexian is a chemically synthesized, small molecule that binds to and inhibits the activity of the active, catalytic site of FXIa. Through selective inhibition of the …

2022年4月9日 · Direct-acting oral anticoagulant use for stroke prevention in atrial fibrillation is limited by bleeding concerns. Asundexian, a novel, oral small molecule activated coagulation …

2024年9月1日 · Asundexian was associated with a higher incidence of stroke or systemic embolism, but less major bleeding, compared with apixaban among patients with atrial …

2024年9月1日 · In this trial involving high-risk patients with atrial fibrillation, researchers assessed whether asundexian Asundexian is a direct, selective inhibitor of activat-would provide a net …

2023年11月6日 · OCEANIC AFINA is a Phase III study investigating asundexian as a potential treatment in patients (≥65 years of age) with atrial fibrillation (AF) at high risk for stroke or …